Amedisys, Inc. (NASDAQ:AMED) Shares Sold by HighTower Advisors LLC

HighTower Advisors LLC lessened its stake in Amedisys, Inc. (NASDAQ:AMED) by 21.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,742 shares of the health services provider’s stock after selling 731 shares during the period. HighTower Advisors LLC’s holdings in Amedisys were worth $249,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Blue Trust Inc. increased its holdings in shares of Amedisys by 55.1% in the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock valued at $34,000 after acquiring an additional 124 shares during the period. HBW Advisory Services LLC acquired a new position in Amedisys in the fourth quarter valued at $38,000. Versant Capital Management Inc raised its holdings in shares of Amedisys by 68.5% in the fourth quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock valued at $41,000 after buying an additional 183 shares during the last quarter. Venturi Wealth Management LLC boosted its stake in shares of Amedisys by 397.4% during the fourth quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider’s stock worth $89,000 after buying an additional 779 shares during the period. Finally, KBC Group NV grew its holdings in shares of Amedisys by 76.8% during the fourth quarter. KBC Group NV now owns 1,158 shares of the health services provider’s stock worth $105,000 after buying an additional 503 shares during the last quarter. Institutional investors and hedge funds own 94.36% of the company’s stock.

Amedisys Stock Performance

Shares of AMED stock opened at $92.98 on Thursday. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. The stock has a 50 day simple moving average of $92.32 and a 200-day simple moving average of $92.35. The company has a market cap of $3.05 billion, a price-to-earnings ratio of 36.90, a price-to-earnings-growth ratio of 1.78 and a beta of 0.76. Amedisys, Inc. has a 12-month low of $82.15 and a 12-month high of $98.95.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Wednesday, February 26th. The health services provider reported $0.96 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.05 by ($0.09). The business had revenue of $598.05 million during the quarter, compared to analysts’ expectations of $602.38 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. On average, equities analysts forecast that Amedisys, Inc. will post 4.4 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Stephens reiterated an “equal weight” rating and issued a $101.00 target price on shares of Amedisys in a research note on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, Amedisys presently has a consensus rating of “Hold” and a consensus target price of $101.00.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.